Health state utilities for relapsed or refractory large B-cell lymphoma treatments: a time trade-off study in the Japanese general population

Key Points

• The study aims to assess health state utilities for treatments of relapsed or refractory large B-cell lymphoma in the Japanese general population.
• Conducted a time trade-off study
• Assessed general population preferences
• Compared administration of epcoritamab with other therapies
• Epcoritamab's subcutaneous injection and outpatient administration is preferred by the general population.
• Improved quality of life was reported regardless of other therapies' efficacy and safety.